Systemic Treatment of Non-Small Cell Lung Cancer

This pocketbook summarises the latest evidence-based and practical information on the use of systemic therapies in the management of non-small cell lung cancer (NSCLC) for early stage, locally advanced, and metastatic disease.

Lung cancer is the leading cause of cancer mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all cases of lung cancer. Most patients present with advanced disease and five-year survival is low at about 15%. Surgery is the main treatment for early stage disease. If patients are deemed inoperable, systemic chemotherapy is considered. For patients with locally advanced disease, multimodality therapy is administered where chemotherapy is given in combination with definitive radiation therapy or surgery in selected cases. Cytotoxic chemotherapy regimens mainly consist of a platinum doublet. Biologic agents are increasingly being incorporated into treatment regimens. This pocketbook summarises the latest evidence-based and practical information on the use of systemic therapies in the management of non-small cell lung cancer (NSCLC), for early stage, locally advanced, and metastatic disease. Including contributions from leading thoracic oncologists from North America and Europe, the book covers the range of therapies currently available to clinicians including cytotoxic chemotherapy, biologic therapies, and other novel agents. This book will serve as an invaluable reference for all health care professionals involved in the management of patients with NSCLC.